Advertisement

Topics

MVA-BN®-HER2 Vaccine in Locally Advanced & Advanced HER2+ Breast Cancer (Gene Transfer Protocol)

2014-07-24 14:00:44 | BioPortfolio

Summary

Primary Objectives:

To evaluate the safety of MVA-BN-HER2 in women with HER-2-positive breast cancer.

Secondary Objectives:

To evaluate the ability of MVA-BN-HER2 to generate humoral and cellular immune responses to HER-2, and to evaluate the duration of these responses.

Exploratory analysis comparing the ability of MVA-BN-HER2 to generate humoral and cellular immune responses to Her-2 in high risk stage III patients who have completed adjuvant chemotherapy and Trastuzumab and stage IV breast cancer patients who must receive ongoing therapy for metastatic disease.

Feasibility of completing 6 vaccines in this high risk patient population.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Breast Cancer

Intervention

MVA-BN-HER2 Vaccine

Location

Stanford University School of Medicine
Stanford
California
United States
94305

Status

Not yet recruiting

Source

Stanford University

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-07-24T14:00:44-0400

Clinical Trials [6596 Associated Clinical Trials listed on BioPortfolio]

HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer

The purpose of this study is to learn more about how to treat patients with HER-2/neu positive invasive breast cancer (IBC). HER-2/neu is a type of protein that is known to be over-express...

Immune Response in Patients Who Have Undergone Vaccine Therapy for Stage III or Stage IV Breast Cancer That Overexpresses HER2

RATIONALE: Studying the immune response to a vaccine made from HER2/neu protein may help doctors plan better treatment for patients with breast cancer that overexpresses HER2. PURPOSE: Th...

A Study of a HER2/Neu Vaccine for Stage IIIB, IIIC and IV HER2/Neu Positive Breast Cancer Patients on Herceptin

This is a phase II, single arm (no placebo, no randomization) study in patients who: - Have HER2 overexpressing Stage IIIB, IIIC or IV breast cancer - Have been treated with Hercep...

Study of Combination Immunotherapy for the Generation of HER-2/Neu Specific Cytotoxic T Cells

This will be a single arm phase I-II single institution clinical trial in patients with HER2 overexpressing Stage IV breast and ovarian cancer who are on maintenance trastuzumab alone afte...

Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1

The purpose of this study is to learn more about how to treat patients with a diagnosis of diagnosis of Human Epidermal Growth Factor Receptor 2/neu (HER-2/neu) positive breast cancer in t...

PubMed Articles [15277 Associated PubMed Articles listed on BioPortfolio]

LMO4 mediates trastuzumab resistance in HER2 positive breast cancer cells.

Breast cancer is the leading cause of cancer-related mortality in women worldwide. Trastuzumab (Herceptin) is an effective antibody drug for HER2 positive breast cancer; or acquired trastuzumab resis...

The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression.

AXL is activated by its ligand GAS6 and is expressed in triple-negative breast cancer cells. In the current study, we report AXL expression in HER2-positive (HER2) breast cancers where it correlates w...

HER2-Based Immunotherapy for Breast Cancer.

Resistance to therapies and disease recurrences after surgery or treatment are common challenges in breast cancer management in clinic. Active immunotherapy using human epidermal growth factor recepto...

Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience.

Several human epidermal growth factor 2 (HER2)-targeted regimens are used to treat HER2-positive (HER2) breast cancer (BC). The goal of this study was to retrospectively determine the pathologic compl...

Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients.

HER2+ metastatic breast cancer (MBC) is a poor prognosis disease, unusually curable. To date, no predictive factors have been clearly correlated with long-term response to anti-HER2 agents.

Medical and Biotech [MESH] Definitions

A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed.

Abnormal accumulation of lymph in the arm, shoulder and breast area associated with surgical or radiation breast cancer treatments (e.g., MASTECTOMY).

Metastatic breast cancer characterized by EDEMA and ERYTHEMA of the affected breast due to LYMPHATIC METASTASIS and eventual obstruction of LYMPHATIC VESSELS by the cancer cells.

A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumors in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1205)

A deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.

More From BioPortfolio on "MVA-BN®-HER2 Vaccine in Locally Advanced & Advanced HER2+ Breast Cancer (Gene Transfer Protocol)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...


Searches Linking to this Trial